fda banning compounded semaglutide moves to remove GLP-1 medications from 503B Bulks List July 29, 2024: FDA issued

It's a triple-agonist, targeting three different receptors: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors

they're digested more slowly than animal proteins, extending the semaglutide effect

Key takeaways Wegovy is a glucagon-like peptide-1 (GLP-1) agonist available in a weekly injection or daily tablet

There is also the issue of treatment fatigue

Paper application: If youre using the paper version of the application, ensure all sections are completed, including both the patient and prescriber sections

The maintenance doses used in these trials include: 4 mg once weekly 9 mg once weekly 12 mg once weekly For those taking the maximum 12 mg dose , they follow a gradual increase that looks like this: 2 mg 4 mg 6 mg 9 mg 12 mg (highest dose studied) Each increase happens every 4 weeks , similar to the phase 2 studies, so the full build-up takes about 16 weeks before staying at 12 mg for the rest of the study